Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Goodwill (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Goodwill for 6 consecutive years, with $16.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Goodwill changed N/A year-over-year to $16.7 million, compared with a TTM value of $16.7 million through Jun 2025, changed N/A, and an annual FY2024 reading of $16.7 million, up 2.97% over the prior year.
  • Goodwill was $16.7 million for Q2 2025 at Cytek Biosciences, roughly flat from $16.7 million in the prior quarter.
  • Across five years, Goodwill topped out at $19.1 million in Q1 2023 and bottomed at $476000.0 in Q2 2021.
  • Average Goodwill over 5 years is $11.8 million, with a median of $10.1 million recorded in 2021.
  • The sharpest move saw Goodwill soared 2031.09% in 2021, then changed 0.0% in 2022.
  • Year by year, Goodwill stood at $10.1 million in 2021, then changed by 0.0% to $10.1 million in 2022, then skyrocketed by 59.53% to $16.2 million in 2023, then rose by 2.97% to $16.7 million in 2024, then increased by 0.26% to $16.7 million in 2025.
  • Business Quant data shows Goodwill for CTKB at $16.7 million in Q2 2025, $16.7 million in Q4 2024, and $16.2 million in Q4 2023.